Logo

Madrigal Provides Update in the P-III (MAESTRO-NAFLD-1) Trial of Resmetirom for the Treatment of Non-Alcoholic Steatohepatitis

Share this

Madrigal Provides Update in the P-III (MAESTRO-NAFLD-1) Trial of Resmetirom for the Treatment of Non-Alcoholic Steatohepatitis

Shots:

  • The P-III (MAESTRO-NAFLD-1) trial evaluates resmetirom (100/80mg, qd) vs PBO in a ratio (1:1:1) in 1200 patients with NAFLD for 52wks. The results which were expected in YE 2021, now expected in Jan 2022
  • The 1EPs of the study is to evaluate the safety & tolerability of resmetirom & 2EPs include LDL-cholesterol, apolipoprotein B, TG lowering & reduction of liver fat as determined by MRI-PDFF. Additionally, exploratory EPs will be evaluated including a reduction in liver enzymes, FibroScan scores, other fibrosis & inflammatory biomarkers
  • The therapy is also being evaluated in the P-III (MAESTRO-NASH) study in a ratio (1:1:1) in 900 patients with liver biopsy-confirmed NASH

Ref: Globe Newswire | Image: Madrigal 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions